Does ADAGRASIB Cause Malignant neoplasm progression? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Malignant neoplasm progression have been filed in association with ADAGRASIB (KRAZATI). This represents 1.1% of all adverse event reports for ADAGRASIB.
10
Reports of Malignant neoplasm progression with ADAGRASIB
1.1%
of all ADAGRASIB reports
3
Deaths
5
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ADAGRASIB?
Of the 10 reports, 3 (30.0%) resulted in death, 5 (50.0%) required hospitalization, and 1 (10.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADAGRASIB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does ADAGRASIB Cause?
Death (272)
Diarrhoea (113)
Hospitalisation (108)
Nausea (87)
Vomiting (79)
Off label use (70)
Asthenia (61)
Fatigue (51)
Decreased appetite (43)
Dehydration (35)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ADAGRASIB Alternatives Have Lower Malignant neoplasm progression Risk?
ADAGRASIB vs ADALIMUMAB
ADAGRASIB vs ADALIMUMAB-AACF
ADAGRASIB vs ADALIMUMAB-AATY
ADAGRASIB vs ADALIMUMAB-ADAZ
ADAGRASIB vs ADALIMUMAB-ADBM